Impact of CYBA genotypes on severity and progression of multiple sclerosis.
Andreas TörnellRoberta KiffinSara HaghighiNatalia MossbergOluf AndersenKristoffer HellstrandAnna MartnerPublished in: European journal of neurology (2022)
These results implicate NOX2 in MS, in particular for the development of secondary progressive disease, and point toward NOX2-reductive therapy aiming to delay secondary progression.